


About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Nine Areas



Dermatology



Nephrology



Gastroenterology



CNS



Rheumatology



Ophthalmology



Hematology



Oncology

**NEW
IN 2026!**



Market Access

This is a guide to the publications Spherix will produce in 2026. It is organized by therapeutic area, indication, and deliverable.

Type of Publications

MARKET DYNAMIX

A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.

REALTIME DYNAMIX

A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.

LAUNCH DYNAMIX

Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

PATIENT CHART DYNAMIX

A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns and uncovers the "why" behind treatment decisions.

PATIENT VOICE DYNAMIX

An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.

ACCOUNT MANAGEMENT DYNAMIX

Identify best practices to build high-performing national and regional account teams and benchmark your performance against competitors.

BENEFIT DESIGN DYNAMIX

Understand and predict market access trends and policy shifts affecting formulary management and reimbursement across commercial and government channels.

KEY ACCOUNT DYNAMIX

Gain strategic account intelligence on leading national and regional payers, IDNs, and specialty pharmacy accounts to support prioritization, engagement strategy, and planning.

PATIENT SERVICES DYNAMIX

Uncover best practices and comparative intelligence on indication and brand-level patient service programs and competencies.

SPECIAL TOPIX

Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit
www.clientportal.spherixglobalinsights.com

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.



BENEFIT DESIGN DYNAMIX

Commercial Trends	- Market & Stakeholder Landscape - Pharmacy Benefits - Medical Benefits - Employer Trends & Influence
Government Trends	- Market & Stakeholder Landscape - Medicare Part D Benefits - Medicare Part B Benefits - Trends in Medicaid, Exchanges & Other Programs

KEY ACCOUNT DYNAMIX

Comparative Assessments	- Leading Accounts - Blues & Regional Plans - Integrated Delivery Networks - Specialty Pharmacies
Account Profiles	- Leading Accounts (19 profiles) - Blues & Regional Plans (40 profiles) - Integrated Delivery Networks (50 profiles) - Specialty Pharmacies (16 profiles)

ACCOUNT MANAGEMENT DYNAMIX

Payer Benchmarking	- Medical Directors - Pharmacy Directors - Annual Review
IDN Benchmarking	- Medical Directors - Pharmacy Directors - Annual Review

PATIENT SERVICES DYNAMIX

- Patient Services Program Benchmarking - Patient Services Best Practices	Available in: - Autoimmune - Oncology - Orphan/Rare - Women's Health
---	---

SPECIAL TOPIX

Pathways Influence in Oncology
--

Key

BENEFIT DESIGN DYNAMIX	Explore commercial and government payer, physician and employer market experiences
KEY ACCOUNT DYNAMIX	Reports use detailed data from key decision-makers from leading national payers, regional payers, IDNs and specialty pharmacies.
ACCOUNT MANAGEMENT DYNAMIX	Reports use extensive data from medical directors and pharmacy directors at payers and IDNs.
PATIENT SERVICES DYNAMIX	Assesses physician, office staff, patient and caregiver experiences with patient service programs and attributes
SPECIAL TOPIX	Current events on specific interest areas Current events



Alopecia Areata

MARKET DYNAMIX	Alopecia Areata, US
LAUNCH DYNAMIX	Leqselvi (SUN Pharma) in Alopecia Areata, US

Atopic Dermatitis

MARKET DYNAMIX	Atopic Dermatitis, JP
REALTIME DYNAMIX	- Atopic Dermatitis, US - Atopic Dermatitis, EU5
LAUNCH DYNAMIX	- Ebglyss (Eli Lilly) in Atopic Dermatitis, US - Nemluvio (Galderma) in Atopic Dermatitis, US - Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	- Atopic Dermatitis, US - Atopic Dermatitis, EU5

Chronic Spontaneous Urticaria

MARKET DYNAMIX	Chronic Spontaneous Urticaria, US
LAUNCH DYNAMIX	- Dupixent (Sanofi/Regeneron) in CSU, US - Rhapsido (Novartis) in CSU, US
PATIENT CHART DYNAMIX	Chronic Spontaneous Urticaria, US

Hidradenitis Suppurativa

MARKET DYNAMIX	Hidradenitis Suppurativa, US
LAUNCH DYNAMIX	Bimzelx (UCB) in Hidradenitis Suppurativa, US

Plaque Psoriasis

REALTIME DYNAMIX	- Plaque Psoriasis, US - Plaque Psoriasis, EU5
LAUNCH DYNAMIX	Icotyde (J&J) in Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	Plaque Psoriasis, US
SPECIAL TOPIX	The Oral Opportunity in Plaque Psoriasis, US

Prurigo Nodularis

MARKET DYNAMIX	Prurigo Nodularis, US
LAUNCH DYNAMIX	Nemluvio (Galderma) in Prurigo Nodularis, US

Other Dermatology Indications

MARKET DYNAMIX	Vitiligo, US
SPECIAL TOPIX	Biologic Coordinators Across Dermatology, US

Dermatology-Adjacent Indications

MARKET DYNAMIX	- Asthma, US - Asthma, EU - Chronic Obstructive Pulmonary Disease, US - Chronic Obstructive Pulmonary Disease, EU
----------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



Eosinophilic Esophagitis	
MARKET DYNAMIX	Eosinophilic Esophagitis, US
Inflammatory Bowel Disease	
MARKET DYNAMIX	- Crohn's Disease, JP - Ulcerative Colitis, JP
REALTIME DYNAMIX	- Crohn's Disease, US - Crohn's Disease, EU5 - Ulcerative Colitis, US - Ulcerative Colitis, EU5
LAUNCH DYNAMIX	- Tremfya (J&J) in Crohn's Disease, US - OmvoH (Eli Lilly) in Crohn's Disease, US - Tremfya (J&J) in Ulcerative Colitis, US
PATIENT CHART DYNAMIX	- Inflammatory Bowel Disease New Starts, US - Inflammatory Bowel Disease Switching, US
PATIENT VOICE DYNAMIX	Inflammatory Bowel Disease, US
SPECIAL TOPIX	- Biologic Coordinators in Gastroenterology, US - The Role of APPs in IBD

Obesity	
MARKET DYNAMIX	Obesity, US
LAUNCH DYNAMIX	- Wegovy Pill (Novo Nordisk) in Obesity, US - Orforglipron (Eli Lilly) in Obesity, US - CagriSema (Novo Nordisk) in Obesity, US

MASH	
MARKET DYNAMIX	- MASH, US - MASH, EU5
LAUNCH DYNAMIX	- Rezdiffra (Madrigal) in MASH, US - Wegovy (Novo Nordisk) in MASH, US
PATIENT CHART DYNAMIX	MASH, US
SPECIAL TOPIX	MASH Screening and Management among PCPs and Endocrinologists, US
Other Gastroenterology Indications	
MARKET DYNAMIX	- Celiac Disease, US - Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US (2025)
LAUNCH DYNAMIX	- Iqirvo (Ipsen) in Primary Biliary Cholangitis, US - Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US - Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US
SPECIAL TOPIX	The Business of Gastroenterology, US

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas



Lupus	
MARKET DYNAMIX	• Cutaneous Lupus, US (2026) • Systemic Lupus Erythematosus, US • Systemic Lupus Erythematosus Pipeline, US • Systemic Lupus Erythematosus, EU5 • Lupus Nephritis, China
REALTIME DYNAMIX	• Lupus Nephritis, US • Lupus Nephritis, EU5 • Lupus Nephritis, Brazil • Lupus Nephritis, Canada
LAUNCH DYNAMIX	• Gazyva (Genentech) in Lupus Nephritis, US • Saphnelo SC (AstraZeneca) in Systemic Lupus Erythematosus, US
PATIENT CHART DYNAMIX	• Lupus Nephritis, US • Systemic Lupus Erythematosus , US • Systemic Lupus Erythematosus & Lupus Nephritis, EU5 • Cutaneous Lupus, US
PATIENT VOICE DYNAMIX	• Systemic Lupus Erythematosus & Lupus Nephritis, US

Spondyloarthritis (AS, nr-AxSpA, and PsA)	
MARKET DYNAMIX	• Ankylosing Spondylitis & nr-AxSpA, US • Ankylosing Spondylitis & nr-AxSpA, EU5 (2025) • Psoriatic Arthritis, EU5 (2025)
REALTIME DYNAMIX	• Psoriatic Arthritis, US
LAUNCH DYNAMIX	• Bimzelx (UCB) in AS & nr-AxSpA, US • Bimzelx (UCB) in Psoriatic Arthritis, US • Sotyktu (BMS) in Psoriatic Arthritis, US

Other Rheumatology Indications	
MARKET DYNAMIX	• Idiopathic Inflammatory Myopathies, US (2026 Refresh) • Rheumatoid Arthritis, US (2026 Refresh) • Rheumatoid Arthritis, EU5 (2025) • Sjogren's Disease, US (2026 Refresh) • Systemic Sclerosis, US
LAUNCH DYNAMIX	• Rinvoq (AbbVie) in Giant Cell Arteritis, US • Cosentyx (Novartis) in PMR, US* • Brepocitinib (Priovent Therapeutics) in Dermatomyositis , US*
PATIENT VOICE DYNAMIX	• Systemic Sclerosis, US
SPECIAL TOPIX	• ILD in Rheumatology, US (2026) • Cell Therapy in Rheumatology, US • Biologic Coordinators Across Rheumatology, US

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



2026 Nephrology Publications

Glomerular Disease		CKD, Dialysis & Transplant	
MARKET DYNAMIX	- Focal Segmental Glomerulosclerosis, US - Membranous Nephropathy, US	MARKET DYNAMIX	Transplant/AMR, US
REALTIME DYNAMIX	- IgA Nephropathy, US - IgA Nephropathy, EU5	REALTIME DYNAMIX	- Dialysis–Nephrologist, US - Dialysis, Renal Dietitian/NP/PA, US
LAUNCH DYNAMIX	- Fabhalta (Novartis) in C3G, US - Empaveli (Apellis) in C3G, US - Fabhalta (Novartis) in IgAN, US - Vanrafia (Novartis) in IgAN, US - Voyxact (Otsuka) in IgAN, US - Filspari (Traverse) in FSGS, US - Atacicept (Vera) in IgAN, US* - Povetacicept (Vertex) in IgAN, US*	LAUNCH DYNAMIX	OLC (Unicycive) in Hyperphosphatemia, US*
PATIENT CHART DYNAMIX	- Focal Segmental Glomerulosclerosis, US - IgA Nephropathy, US - IgA Nephropathy, EU5 - IgA Nephropathy, JP - IgA Nephropathy, China	PATIENT CHART DYNAMIX	- Chronic Kidney Disease, Non-Dialysis, Nephrologist, US - Chronic Kidney Disease, Non-Dialysis, PCP, US - Dialysis, US
PATIENT VOICE DYNAMIX	IgA Nephropathy, US	PATIENT VOICE DYNAMIX	Chronic Kidney Disease, US
SPECIAL TOPIX	Feedback from ASN Kidney Week, US		

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



Alzheimer’s Disease

MARKET DYNAMIX	Alzheimer’s Disease, US
----------------	---

Migraine

REALTIME DYNAMIX	Migraine (Neurologists & PCPs), US
------------------	--

Multiple Sclerosis

MARKET DYNAMIX	Multiple Sclerosis, US
PATIENT VOICE DYNAMIX	Multiple Sclerosis, US
SPECIAL TOPIX	Post-ACTRIMS/ECTRIMS Coverage

Psychiatric Indications

MARKET DYNAMIX	- Behavioral and Psychiatric Symptoms in Alzheimer’s, US - Depressive Mood Disorders, US - Schizophrenia, US
----------------	--

Generalized Myasthenia Gravis

REALTIME DYNAMIX	- Generalized Myasthenia Gravis, US - Generalized Myasthenia Gravis, EU5
PATIENT CHART DYNAMIX	- Generalized Myasthenia Gravis, US - Generalized Myasthenia Gravis, EU5
PATIENT VOICE DYNAMIX	Generalized Myasthenia Gravis, US
LAUNCH DYNAMIX	- Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US - Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US - Gefurulimab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US* - Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*

Other CNS Indications

MARKET DYNAMIX	Chronic Inflammatory Demyelinating Polyneuropathy, US
SPECIAL TOPIX	- Biologic Coordinators in Neurology - Cell Therapy in Neurology Indications, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	Diabetic Macular Edema & AMD, US
------------------	--

Other Ophthalmology Indications

MARKET DYNAMIX	- Diabetic Retinopathy, US - Geographic Atrophy, US (2025) - Thyroid Eye Disease (TED), US (2025)
SPECIAL TOPIX	Gene Therapies in Retina, US

Neovascular Age-Related Macular Degeneration

PATIENT CHART DYNAMIX	Age-Related Macular Degeneration, US
-----------------------	--

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas



Bleeding Disorders

MARKET DYNAMIX	- Hemophilia A & B, US - Hemophilia A & B, EU5 - Von Willebrand Disease, US
LAUNCH DYNAMIX	- Qfitlia (Sanofi) in Hemophilia A & B, US - Hympavzi (Pfizer) in Hemophilia A & B, US - Alhemo (Novo Nordisk) in Hemophilia A & B, US - Mim8 (Novo Nordisk) in Hemophilia A, US*
PATIENT VOICE DYNAMIX	People with Bleeding Disorders
SPECIAL TOPIX	Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders
PATIENT CHART DYNAMIX	People with Bleeding Disorders

Hemoglobinopathies

MARKET DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
LAUNCH DYNAMIX	Aqvesme (Agiros Pharmaceuticals) in Thalassemia, US
PATIENT CHART DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
PATIENT VOICE DYNAMIX	Sickle Cell Disease, US

Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US
----------------	---

Other Benign Hematology Indications

MARKET DYNAMIX	- Warm Autoimmune Hemolytic Anemia (w-AIHA) - Immune Thrombocytopenic Purpura (ITP)
LAUNCH DYNAMIX	- Nipocalimab (J&J) in w-AIHA, US* - Wayrilz (Sanofi) in ITP, US

Other Hematology Indications

SPECIAL TOPIX	AI in Hematology and Oncology, US (2026)
---------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



Hematologic Oncology	
Acute Myeloid Leukemia	
LAUNCH DYNAMIX	- Komzifti (Kura) in Acute Myeloid Leukemia, US - Revuforj (Syndax) in Acute Myeloid Leukemia, US
MARKET DYNAMIX	Acute Myeloid Leukemia, US
B-Cell Malignancies	
MARKET DYNAMIX	- B-Cell Malignancies, US - Large B-Cell Lymphoma, EU
PATIENT CHART DYNAMIX	- Large B-Cell Lymphoma, US - Chronic Lymphocytic Leukemia, US
PATIENT VOICE DYNAMIX	B-Cell Malignancies, US
Multiple Myeloma	
MARKET DYNAMIX	Multiple Myeloma, EU5
REALTIME DYNAMIX	Multiple Myeloma, US
LAUNCH DYNAMIX	- Lynozytic (Regeneron) in Multiple Myeloma, US - Blenrep (GSK) in Multiple Myeloma, US - Darzalex Faspro (J&J) in High-Risk Smoldering Multiple Myeloma, US
PATIENT CHART DYNAMIX	Multiple Myeloma, US
PATIENT VOICE DYNAMIX	Multiple Myeloma, US
SPECIAL TOPIX	High-Risk Smoldering Multiple Myeloma, US
Myeloproliferative Neoplasms (MPN)	
MARKET DYNAMIX	Myeloproliferative Neoplasms, US

Medical Oncology	
Solid Tumors	
REALTIME DYNAMIX	PD-1 Inhibition in Solid Tumors, US
MARKET DYNAMIX	Non-Small Cell Lung Cancer, US
Other Oncology Indications	
SPECIAL TOPIX	AI in Hematology and Oncology, US (2026)

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas

Visit The Spherix Portal



Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at
www.clientportal.spherixglobalinsights.com